Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 5
1977 5
1978 8
1979 13
1980 12
1981 5
1982 5
1983 8
1984 10
1985 5
1986 9
1987 2
1988 2
1989 4
1990 13
1991 1
1992 14
1993 14
1994 9
1995 5
1996 2
1997 5
1998 5
1999 5
2000 5
2001 4
2002 12
2003 1
2004 7
2005 7
2006 14
2007 12
2008 4
2009 9
2010 20
2011 23
2012 29
2013 32
2014 29
2015 25
2016 27
2017 23
2018 28
2019 23
2020 32
2021 34
2022 22
2023 35
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

590 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for hae i ii
Search for Hae-Ri Wi instead (2 results)
Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).
Wedner HJ. Wedner HJ. Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S14-S17. doi: 10.2500/aap.2020.41.200081. Allergy Asthma Proc. 2020. PMID: 33109319 Review.
The pathophysiology of hereditary angioedema (HAE) in virtually all cases is the result of the uncontrolled production of the vasoactive peptide bradykinin. ...Failure to adequately control the production of bradykinin is thus the major mechanism for HAE. Several ot …
The pathophysiology of hereditary angioedema (HAE) in virtually all cases is the result of the uncontrolled production of the vasoact …
Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology.
Sinnathamby ES, Issa PP, Roberts L, Norwood H, Malone K, Vemulapalli H, Ahmadzadeh S, Cornett EM, Shekoohi S, Kaye AD. Sinnathamby ES, et al. Adv Ther. 2023 Mar;40(3):814-827. doi: 10.1007/s12325-022-02401-0. Epub 2023 Jan 7. Adv Ther. 2023. PMID: 36609679 Free PMC article. Review.
HAE affects 1/50,000 people worldwide. Three main types of HAE exist: type I, type II, and type III. ...C1-INH is important in the coagulation complement, contact systems, and fibrinolysis. Most HAE cases are type I. Type I and II HAE res …
HAE affects 1/50,000 people worldwide. Three main types of HAE exist: type I, type II, and type III. ...C1-INH is impor …
Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Beard N, et al. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. Cochrane Database Syst Rev. 2022. PMID: 36326435 Free PMC article. Review.
People with Type I HAE (approximately 80% of all HAE cases) have insufficient amounts of C1 esterase inhibitor (C1-INH) protein; people with Type II HAE (approximately 20% of all cases) may have normal C1-INH concentrations, but, due to genetic mutatio …
People with Type I HAE (approximately 80% of all HAE cases) have insufficient amounts of C1 esterase inhibitor (C1-INH) protei …
Bradykinin-mediated diseases.
Kaplan AP. Kaplan AP. Chem Immunol Allergy. 2014;100:140-7. doi: 10.1159/000358619. Epub 2014 May 22. Chem Immunol Allergy. 2014. PMID: 24925394 Review.
Most cases have an IgG autoantibody to C1 inhibitor which inactivates it so that the presentation is strikingly similar to type I HAE. New therapies for types I and II HAE include C1 inhibitor replacement therapy, ecallantide, a kallikrein antagonist, and ica …
Most cases have an IgG autoantibody to C1 inhibitor which inactivates it so that the presentation is strikingly similar to type I HAE …
Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.
Farkas H, Debreczeni ML, Kőhalmi KV. Farkas H, et al. Expert Opin Investig Drugs. 2018 Jan;27(1):87-103. doi: 10.1080/13543784.2018.1415325. Epub 2017 Dec 15. Expert Opin Investig Drugs. 2018. PMID: 29226721 Review.
By contrast, the investigational medicinal products under evaluation in Phase I and II clinical trials are targeted at the prevention of HAE attacks. ...This review summarizes the status and the findings of the currently ongoing Phase I and Phase II clinical …
By contrast, the investigational medicinal products under evaluation in Phase I and II clinical trials are targeted at the prevention …
Lanadelumab: First Global Approval.
Syed YY. Syed YY. Drugs. 2018 Oct;78(15):1633-1637. doi: 10.1007/s40265-018-0987-2. Drugs. 2018. PMID: 30267321 Review.
Shire is developing lanadelumab (Takhzyro) for the prevention of hereditary angioedema (HAE) attacks. Lanadelumab is a fully human monoclonal antibody that inhibits plasma kallikrein. ...Subcutaneous administration of lanadelumab significantly reduced HAE attacks ve …
Shire is developing lanadelumab (Takhzyro) for the prevention of hereditary angioedema (HAE) attacks. Lanadelumab is a fully human mo …
Managing Diagnosis, Treatment, and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor.
Jones D, Zafra H, Anderson J. Jones D, et al. J Asthma Allergy. 2023 Apr 22;16:447-460. doi: 10.2147/JAA.S398333. eCollection 2023. J Asthma Allergy. 2023. PMID: 37124440 Free PMC article. Review.
Mutations in SERPING1 lead to deficient (type I HAE-C1-INH) or dysfunctional (type II HAE-C1-INH) C1-INH protein and subsequent dysregulation of the kallikrein-bradykinin cascade. However, some patients present with a third type of HAE (HAE-nI-C …
Mutations in SERPING1 lead to deficient (type I HAE-C1-INH) or dysfunctional (type II HAE-C1-INH) C1-INH protein and su …
The multifactorial impact of receiving a hereditary angioedema diagnosis.
Raasch J, Glaum MC, O'Connor M. Raasch J, et al. World Allergy Organ J. 2023 Jun 30;16(6):100792. doi: 10.1016/j.waojou.2023.100792. eCollection 2023 Jun. World Allergy Organ J. 2023. PMID: 37448849 Free PMC article. Review.
The most frequent cause of HAE is a mutation in the serpin family G member 1 (SERPING1) gene, which either leads to deficient plasma levels of the C1-esterase inhibitor (C1-INH) protein (type I HAE-C1-INH) or normal plasma levels of dysfunctional C1-INH protein (typ …
The most frequent cause of HAE is a mutation in the serpin family G member 1 (SERPING1) gene, which either leads to deficient plasma …
Risk of angioedema following invasive or surgical procedures in HAE type I and II--the natural history.
Aygören-Pürsün E, Martinez Saguer I, Kreuz W, Klingebiel T, Schwabe D. Aygören-Pürsün E, et al. Allergy. 2013 Aug;68(8):1034-9. doi: 10.1111/all.12186. Allergy. 2013. PMID: 23968383 Free PMC article. Clinical Trial.
OBJECTIVES: This analysis examined rates of perioperative edema in patients with HAE not receiving prophylaxis. METHODS: This was a retrospective analysis of records of randomly selected patients with HAE type I or II treated at the Frankfurt Comprehensive Ca …
OBJECTIVES: This analysis examined rates of perioperative edema in patients with HAE not receiving prophylaxis. METHODS: This was a r …
Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema.
de Maat S, Joseph K, Maas C, Kaplan AP. de Maat S, et al. Clin Rev Allergy Immunol. 2021 Jun;60(3):348-356. doi: 10.1007/s12016-021-08837-6. Epub 2021 May 6. Clin Rev Allergy Immunol. 2021. PMID: 33956309 Free PMC article. Review.
Although naturally occurring negatively charged surfaces have shown to be involved in the role of the contact system in thrombosis, such surfaces are elusive in the pathogenesis of bradykinin-driven hereditary angioedema (HAE). In this review, we will explore the molecular …
Although naturally occurring negatively charged surfaces have shown to be involved in the role of the contact system in thrombosis, such sur …
590 results